^
    Back
    Association details:
    Biomarker:CD74-ROS1 F2004L + PD-L1 expression
    Cancer:Lung Adenocarcinoma
    Drug:Lorbrena (lorlatinib) (ALK inhibitor, ROS1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    J Immunother Cancer
    Title:

    Short-term response to immune-chemotherapy and immune features of a ceritinib-resistant patient with ROS1-rearranged lung adenocarcinoma

    Published date:
    02/08/2021
    Excerpt:
    A second NGS assay found a possible resistance mutation of c.6012T>G (p.F2004L)...repeat biopsy tissue sample from the supraclavicular lymph node showed that the expression of PD-L1 in both tumor cells and immune cells was 10%...lorlatinib, which is potent for brain metastases, was administered to the patient (100 mg orally once a day)....previously enlarged lymph nodes also shrank to normal size. The patient continued to take lorlatinib and has not experienced disease progression so far...
    DOI:
    10.1136/jitc-2020-001967
    Test:
    VENTANA PD-L1 (SP142) Assay